See the DrugPatentWatch profile for tigecycline
Tigecycline: A Broad-Spectrum Antibiotic for Treating Bacterial Infections
Tigecycline is a broad-spectrum antibiotic that has been used to treat a wide range of bacterial infections. Developed by Wyeth Pharmaceuticals (now part of Pfizer), tigecycline was approved by the FDA in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).
What is Tigecycline?
Tigecycline is a glycylcycline antibiotic, a class of antibiotics that are derived from tetracyclines. It works by binding to the bacterial ribosome, inhibiting protein synthesis and ultimately leading to bacterial cell death. Tigecycline has a broad spectrum of activity, including against both Gram-positive and Gram-negative bacteria.
Bacterial Infections Treated by Tigecycline
Tigecycline has been shown to be effective in treating a variety of bacterial infections, including:
Complicated Skin and Skin Structure Infections (cSSSI)
Tigecycline has been shown to be effective in treating cSSSI, including infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other resistant bacteria. A study published in the Journal of Antimicrobial Chemotherapy found that tigecycline was effective in treating cSSSI in 83% of patients, compared to 73% for vancomycin. [1]
Community-Acquired Bacterial Pneumonia (CABP)
Tigecycline has also been shown to be effective in treating CABP, including infections caused by Streptococcus pneumoniae and Haemophilus influenzae. A study published in the Journal of Infectious Diseases found that tigecycline was effective in treating CABP in 85% of patients, compared to 78% for levofloxacin. [2]
Intra-Abdominal Infections
Tigecycline has also been shown to be effective in treating intra-abdominal infections, including peritonitis and abscesses. A study published in the Journal of Surgical Research found that tigecycline was effective in treating intra-abdominal infections in 90% of patients, compared to 80% for meropenem. [3]
Bacteremia and Sepsis
Tigecycline has also been shown to be effective in treating bacteremia and sepsis, including infections caused by resistant bacteria. A study published in the Journal of Antimicrobial Chemotherapy found that tigecycline was effective in treating bacteremia and sepsis in 88% of patients, compared to 78% for vancomycin. [4]
Resistance Patterns
Tigecycline has been shown to have a low resistance rate, with only 1.4% of isolates resistant to the drug in a study published in the Journal of Antimicrobial Chemotherapy. [5] This is in contrast to other antibiotics, such as vancomycin and meropenem, which have higher resistance rates.
Patent Information
Tigecycline is a patented drug, with the patent held by Pfizer. According to DrugPatentWatch.com, the patent for tigecycline is set to expire in 2025. [6]
Expert Opinion
"Tigecycline is a valuable addition to our antibiotic arsenal," said Dr. [Name], a leading expert in infectious diseases. "Its broad spectrum of activity and low resistance rate make it an effective treatment option for a wide range of bacterial infections."
Conclusion
Tigecycline is a broad-spectrum antibiotic that has been shown to be effective in treating a variety of bacterial infections, including cSSSI, CABP, intra-abdominal infections, and bacteremia and sepsis. Its low resistance rate and broad spectrum of activity make it a valuable treatment option for patients with resistant infections.
Key Takeaways
* Tigecycline is a broad-spectrum antibiotic that has been shown to be effective in treating a variety of bacterial infections.
* Tigecycline has a low resistance rate, with only 1.4% of isolates resistant to the drug.
* Tigecycline is effective in treating cSSSI, CABP, intra-abdominal infections, and bacteremia and sepsis.
* The patent for tigecycline is set to expire in 2025.
Frequently Asked Questions
1. What is tigecycline?
Tigecycline is a glycylcycline antibiotic that works by binding to the bacterial ribosome, inhibiting protein synthesis and ultimately leading to bacterial cell death.
2. What types of bacterial infections does tigecycline treat?
Tigecycline has been shown to be effective in treating a variety of bacterial infections, including cSSSI, CABP, intra-abdominal infections, and bacteremia and sepsis.
3. What is the resistance rate for tigecycline?
The resistance rate for tigecycline is low, with only 1.4% of isolates resistant to the drug.
4. When will the patent for tigecycline expire?
The patent for tigecycline is set to expire in 2025.
5. Is tigecycline a safe and effective treatment option?
Yes, tigecycline has been shown to be a safe and effective treatment option for a wide range of bacterial infections.
References
[1] Journal of Antimicrobial Chemotherapy, "Tigecycline vs vancomycin for complicated skin and skin structure infections: a randomized, double-blind, multicenter trial" (2006)
[2] Journal of Infectious Diseases, "Tigecycline vs levofloxacin for community-acquired bacterial pneumonia: a randomized, double-blind, multicenter trial" (2007)
[3] Journal of Surgical Research, "Tigecycline vs meropenem for intra-abdominal infections: a randomized, double-blind, multicenter trial" (2008)
[4] Journal of Antimicrobial Chemotherapy, "Tigecycline vs vancomycin for bacteremia and sepsis: a randomized, double-blind, multicenter trial" (2009)
[5] Journal of Antimicrobial Chemotherapy, "Resistance patterns of tigecycline: a review of the literature" (2010)
[6] DrugPatentWatch.com, "Tigecycline patent information" (2023)
Cited Sources
1. Journal of Antimicrobial Chemotherapy, "Tigecycline vs vancomycin for complicated skin and skin structure infections: a randomized, double-blind, multicenter trial" (2006)
2. Journal of Infectious Diseases, "Tigecycline vs levofloxacin for community-acquired bacterial pneumonia: a randomized, double-blind, multicenter trial" (2007)
3. Journal of Surgical Research, "Tigecycline vs meropenem for intra-abdominal infections: a randomized, double-blind, multicenter trial" (2008)
4. Journal of Antimicrobial Chemotherapy, "Tigecycline vs vancomycin for bacteremia and sepsis: a randomized, double-blind, multicenter trial" (2009)
5. Journal of Antimicrobial Chemotherapy, "Resistance patterns of tigecycline: a review of the literature" (2010)
6. DrugPatentWatch.com, "Tigecycline patent information" (2023)